Sarepta Therapeutics downgraded by Piper Sandler with a new price target
$SRPT
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler downgraded Sarepta Therapeutics from Overweight to Neutral and set a new price target of $36.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2025 | $24.00 | Buy → Hold | TD Cowen |
| 6/17/2025 | Peer Perform | Wolfe Research | |
| 6/16/2025 | Overweight → Equal-Weight | Morgan Stanley | |
| 6/16/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 6/16/2025 | Buy → Neutral | BofA Securities | |
| 6/16/2025 | $70.00 | Outperform → Market Perform | BMO Capital Markets |
| 6/16/2025 | $36.00 | Overweight → Neutral | Piper Sandler |
| 6/16/2025 | $10.00 | Neutral → Sell | H.C. Wainwright |
8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)
10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)
DEFA14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)
- The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators - Shipments of ELEVIDYS for infusions in non-ambulatory patients in commercial setting are suspended until enhanced regimen is approved and in place - ENVISION study is paused while seeking a protocol amendment to incorporate additional immunosuppression - Sarepta to host investor call on June 16, 2025, at 8:00 am Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only a
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration. "This is one of the first programs to receive platform technology designation and an important recognition by FDA of the reproducibility and adaptability of this technology across multiple therapeutic programs," said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. We have received feedback from the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) that dosing may continue uninterrupted in ENVISION, study SRP-9001-303. ENVISION is a global, randomized, double-blind, placebo-controlled Phase 3 study of ELEVIDYS in non-ambulatory and older ambulatory individuals with Duchenne. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene mo